Logo

American Heart Association

  114
  0


Final ID: We105

cBIN1 Gene Therapy Improves Left Ventricular Filling Pressure in a Canine Model of Ischemic Dilated Cardiomyopathy

Abstract Body: INTRODUCTION: In heart failure patients, increased left ventricular end diastolic pressure (LVEDP) is pathognomonic of myocardial dysfunction. Previously, we presented that gene therapy with exogeneous cardiac bridging integrator 1 (cBIN1), a membrane scaffolding protein that organizes T-tubule microdomains and is decreased in failing hearts, recovers systolic function in a canine model of chronic ischemic dilated cardiomyopathy (IDCM). The effect of catheter-based delivery of cBIN1 gene therapy on increased LVEDP is unclear.

HYPOTHESIS: We tested the hypothesis that cBIN1 gene therapy improves LVEDP in a canine model of IDCM.

METHODS: Twelve healthy dogs (30±2 kg) underwent left anterior descending artery ligation and developed IDCM with LVEF <40% and NT-proBNP >900 pmol/L over 3–4 months. Animals received a single application at 20 subendocardial LV sites of either AAV9-GFP (control, n=6) or AAV9-cBIN1 (n=6) using a MyoStar catheter-based injection. Pressure-volume loops were acquired in vivo, including measurement of LVEDP, end-systolic pressure-volume relation (ESPVR), isovolumic relaxation time (IVRT) and isovolumetric contraction time (IVCT). Measurements were performed on the day prior to administering the therapy (pre-therapy) and 5–8 weeks post-intramyocardial injection (post-therapy). For statistics, student t-test was used, and p<0.05 refers as significant. Results are reported as mean±SD.

RESULTS: In AAV9-GFP control-treated dogs, compared with pre-therapy, post-therapy LVEDP elevated significantly (13±1 vs. 17±1 mmHg, p=0.002, Figure A), whereas in the cBIN1-treated cohort, elevated LVEDP improved significantly (13±4 vs. 11±3 mmHg, p=0.042). With control therapy, ESPVR exhibited a significant decrease in contractility (1.40±0.44 vs. 1.81±0.49 mmHg/mL, p=0.001, Figure B), whereas cBIN1 therapy caused a substantial improvement in ESPVR (1.54±0.71 vs. 1.34±0.43 mmHg/mL, p=0.022, Figure B). At the post-therapy time-point, compared with control therapy, cBIN1 therapy improved IVRT (96±10 vs. 72±8 ms, p<0.001, Figure C) and IVCT (49±4 vs. 40±3 ms, p=0.009, Figure D).

CONCLUSION: cBIN1 gene therapy reduces elevated LV filling pressure and improves overall hemodynamics in a canine model of chronic IDCM.
  • Khan, Muhammad  ( The University of Utah , Salt Lake City , Utah , United States )
  • Shaw, Robin  ( The University of Utah , Salt Lake City , Utah , United States )
  • Dosdall, Derek  ( The University of Utah , Salt Lake City , Utah , United States )
  • Yazaki, Kyoichiro  ( The University of Utah , Salt Lake City , Utah , United States )
  • Ishidoya, Yuki  ( The University of Utah , Salt Lake City , Utah , United States )
  • Offei, Emmanuel  ( The University of Utah , Salt Lake City , Utah , United States )
  • Ruizcastillo, Sofia  ( The University of Utah , Salt Lake City , Utah , United States )
  • Shah, Ankur  ( The University of Utah , Salt Lake City , Utah , United States )
  • Li, Jing  ( The University of Utah , Salt Lake City , Utah , United States )
  • Palatinus, Joseph  ( The University of Utah , Salt Lake City , Utah , United States )
  • Hong, Tingting  ( The University of Utah , Salt Lake City , Utah , United States )
  • Author Disclosures:
    Muhammad Khan: DO NOT have relevant financial relationships | Robin Shaw: DO have relevant financial relationships ; Ownership Interest:TikkunLevTherapeutics:Active (exists now) | Derek Dosdall: No Answer | Kyoichiro Yazaki: DO NOT have relevant financial relationships | Yuki Ishidoya: No Answer | Emmanuel Offei: No Answer | Sofia Ruizcastillo: No Answer | Ankur Shah: DO NOT have relevant financial relationships | Jing Li: DO NOT have relevant financial relationships | Joseph palatinus: No Answer | Tingting Hong: DO have relevant financial relationships ; Research Funding (PI or named investigator):TikkunLev Inc.:Active (exists now) ; Individual Stocks/Stock Options:TikkunLev Inc.:Active (exists now)
Meeting Info:

Basic Cardiovascular Sciences

2024

Chicago, Illinois

Session Info:

Poster Session and Reception 3

Wednesday, 07/24/2024 , 04:30PM - 07:00PM

Poster Session and Reception

More abstracts on this topic:
A Single-Dose of a Novel CasX-Editor Lowers APOC3 Levels In Vivo

Karanth Santhosh, Ripley-phipps Sterling, Miller Katherine, Su Ali, Mrak Anna, Karmarkar Maitreyee, Eggers Michelle, Bardai Farah, Narsineni Lokesh, Li Yuexuan, Langner Heera, Bucher Simon, Szulwach Keith, Goh Natalie, Mok Amanda, Reimer Kirsten, Oakes Benjamin, Khakoo Aarif, Mirotsou Maria, Smekalova Elena, Saraya Jennifer, Stein Shannon, Sato Anna, Bale Shyamsundhar, Krupa Oleh, Mauriello Anthony

AI and Quantum Sensors:
Realization of a Safe and Effective Unshielded Bedside Magnetocardiogram to Detect Ischemia in the Emergency Room

Iwata Geoffrey, Aschbacher Kirstin, John Sajiny, Tam Simon, Au-yeung Kit Yee, Contreras Johanna, Bhatt Deepak, Bander Jeffrey

More abstracts from these authors:
T-tubule microdomains promote protective mitophagy in failing hearts

Richmond Bradley, Li Jing, Funai Katsuhiko, Shaw Robin, Hong Tingting

Cardiac Favored Transcription of the Exogenous Gene in Mice after A Single Systemic Delivery of AAV9-cBIN1

Ha Thuy, Li Jing, Balmaceda Pia, Shaw Robin, Hong Tingting

You have to be authorized to contact abstract author. Please, Login
Not Available